Vanda Pharmaceuticals Inc. (VNDA:US) rose 5.1 percent to $11.63 and gained 7.4 percent earlier, the most intraday since Oct. 13. The Rockville, Maryland-based drugmaker was rated new “buy” at Jefferies Group Inc., which cited the sale of Vanda’s U.S. and Canadian rights for its schizophrenia drug Fanapt to Novartis AG (NVS:US).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.